Gene Solutions has inked memoranda of understanding with two Chinese diagnostics companies, ZaoDx and MagicBiotech, to deploy its SPOT-MAS multi-cancer early detection test and next-generation sequencing cancer technologies in China. These collaborations include public awareness campaigns and academic research partnerships aiming to adapt and validate these genomic assays for the Chinese clinical landscape. This strategic expansion complements prior deals with Topgen Biomedical and NEWCL Biomedical Laboratory, underscoring the firm’s commitment to penetrating Asian markets and advancing early cancer detection through circulating tumor DNA analysis targeting methylation and DNA fragmentation biomarkers.